Cabaletta Bio Q3 2025 R&D expenses $39.8M; rese-cel BLA submission targeted for 2027

Cabaletta Bio, Inc.

2025-Q3 EPS reported -$1.75 vs consensus -$0.48 ▼ miss (-263.5%)

R&D expenses of $39.8M in Q3 2025, up from $26.3M a year ago; cash $159.9M as of Sep 30, 2025.
Myositis registrational cohort (14 patients) set to begin enrollment by year-end 2025; BLA submission planned for 2027.
FDA alignment on registrational cohort designs for SSc and SLE trials expected by year-end 2025.
EMA granted PRIME designation for rese-cel in myositis; FDA granted RMAT for SLE/LN and Fast Track for gMG.
Steve Gavel appointed Chief Commercial Officer; led CARVYKTI launch at Legend Biotech.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.